JPMorgan Chase & Co. Has $23.28 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

JPMorgan Chase & Co. cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 21.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,901 shares of the company's stock after selling 35,923 shares during the period. JPMorgan Chase & Co. owned approximately 0.44% of Krystal Biotech worth $23,282,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter worth about $40,000. Values First Advisors Inc. purchased a new position in shares of Krystal Biotech in the third quarter worth approximately $53,000. Quest Partners LLC acquired a new stake in shares of Krystal Biotech during the second quarter valued at approximately $71,000. GAMMA Investing LLC raised its holdings in shares of Krystal Biotech by 184.8% during the third quarter. GAMMA Investing LLC now owns 430 shares of the company's stock valued at $78,000 after acquiring an additional 279 shares during the period. Finally, Huntington National Bank lifted its position in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after acquiring an additional 283 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is owned by company insiders.

Analyst Ratings Changes

KRYS has been the topic of several research analyst reports. Chardan Capital reiterated a "buy" rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Stifel Nicolaus lifted their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a report on Wednesday, September 11th. Citigroup increased their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $206.67.

Krystal Biotech Stock Down 1.9 %

Shares of KRYS traded down $3.08 during midday trading on Thursday, reaching $156.67. 227,604 shares of the stock were exchanged, compared to its average volume of 209,081. The company has a market cap of $4.51 billion, a price-to-earnings ratio of 88.51 and a beta of 0.85. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The firm has a 50 day simple moving average of $175.06 and a 200-day simple moving average of $183.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company's revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.67) earnings per share. Research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).